Signal Pharmaceuticals, Inc.

Berlex Laboratories, Inc.

Steven T Sakata

Zuchun Zhao

Kenneth Jay Shaw

Shripad S Bhagwat

John J Sapienza

Shung C Wu

Yoshitaka Satoh

Qi Chao

Damian O Arnaiz

Ronald J Albers

Chris Allen Buhr

Brian D Griedel

Kiran Sahasrabudhe

Veronique Plantevin

Rachel Ferri

Gary Bruce Phillips

Michael M Morrissey

Monica J Kochanny

Bin Ye

Yuo-Ling Chou

Wheeseong Lee

R Michael Snider

Karna Lyn Sacchi

Amy Mei Liang

Rushad E Karanjawala

Heather K Raymon

Wei Xu

William J Guilford

Isaothiazoloanthrones, isooxazoloanthrones, isoindolanthrones, and derivatives thereof having the general formula: 

Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof a JNK inhibitors and compositions and methods related thereto

Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure: wherein R, Rand A are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

Methods of using indazole derivatives as JNK inhibitors

This invention is generally directed to Indazole Derivatives having the following structure: or pharmaceutically acceptable salt thereof, wherein R, Rand A are as defined herein. Such compounds have utility in the treatment of a wide range of diseases and disorders that are responsive to JNK inhibition, such as an inflammatory disease or disorder. Thus, methods of treating such diseases and disorders are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith

Isothiazoloanthrones, isooxazoloanthrones, isoindolanthrones, and derivatives thereof having the general formula:and pharmaceutically acceptable salts thereof, wherein Ris &#x2014;CH&#x2014;, &#x2014;SO&#x2014;, &#x2014;O&#x2014;, &#x2014;SO&#x2014;, or &#x2014;S&#x2014;; compositions comprising the isothiazoloanthrones, isooxazoloanthrones, isoindolanthrones, and derivatives thereof; and methods for treating or preventing a disorder alleviated by inhibiting Jun N-terminal kinase (JNK) by administering the isothiazoloanthrones, isooxazoloanthrones, isoindolanthrones, and derivatives thereof are described herein.

Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof as JNK inhibitors and compositions and methods related

Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure:wherein R, Rand A are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

Indazole derivatives as JNK inhibitors and compositions and methods related thereto

Ortho-anthranilamide derivatives as anti-coagulants

Benzenamine derivatives as anti-coagulants

This invention is directed to compounds of formula (III): ##STR1## wherein B, C, D, E, R.sup.1, R.sup.2 and R.sup.3 are disclosed herein. These compounds are disclosed as being useful as anti-coagulants.

Compounds of formula (I): ##STR1## wherein: n,

Naphthyl-substituted benzimidazole derivatives as anti-coagulants

Growing community of inventors

San Diego, CA, United States of America

Steven T Sakata